Thyroid Eye Disease Market Current Trends Analysis 2026 to 2035
Share With :
Global Thyroid Eye Disease Market Size is valued at USD 2.26 billion in 2024 and is predicted to reach USD 4.02 billion by the year 2034 at a 6.0% CAGR during the forecast period for 2025 to 2034.
Thyroid Eye Disease Market Size, Share & Trends Analysis Report By Marketed Treatment (TEPEZZA (Teprotumumab), By Pipeline Treatment (VRDN 001, VB 421, Batoclimab, Linsitnib), By Region, And By Segment Forecasts, 2026 to 2035
Thyroid Eye Disease is an autoimmune condition that causes eye swelling, bulging, and pain, often linked to Graves' disease. Treatments include Tepezza, corticosteroids, and surgery to reduce symptoms like eye bulging and vision problems.
Improved healthcare settings, improvements in autoimmune disease treatment, and positive patient compliance percentage are factors expected to drive the growth of the global Thyroid Eye Disease market. Increasing research & development activities and rising investment are some of the other factors expected to augment the target market growth. The increasing adoption of artificial tears and lubricating eye drops to alleviate dryness and give temporary relief from discomfort globally is expected to boost the market expansion in the coming years.
However, the high cost of Thyroid Eye Disease and lack of a clear thyroid eye treatment, coupled with the COVID-19 outbreak, are factors that may limit growth of the target market during the forecast period. Furthermore, increasing R&D activities, government actions to use sustainable components for production, investments by prominent players are factors expected to create lucrative growth opportunities in terms of revenue for players operating in the global Thyroid Eye Disease market over the forecast period.
The Thyroid Eye Disease market is segmented on the basis of marketed treatment and pipeline treatment. Based on the marketed treatment, the market is segmented as tepezza (Teprotumumab). By pipeline treatment, the market is segmented into VRDN 001, VB 421, batoclimab, and linsitinib.
The TEPEZZA (Teprotumumab) category is expected to hold a major share of the global Thyroid Eye Disease market in 2023. This is attributed to help in reducing eye bulges and double vision. Additionally, it also decreases the signs and symptoms of thyroid eye disease, including eye pain, edema, and eye disease.
The VRDN-001 segment is projected to grow at a rapid rate in the global Thyroid Eye Disease market owing to growing use in treating several fatal diseases. The VRDN-001 is an intravenous monoclonal antibody that goals the anti-insulin-like growth factor-1 receptor. The major benefit of using VRDN-001 in treating these diseases is that they are taken from a biological source.
The North America Thyroid Eye Disease market is expected to report the most increased market share in terms of revenue. This can be attributed to the strong focus on the treatment of thyroid eye disease in the region. In addition, the growing prevalence of several thyroid diseases and advancement in treatment options for Thyroid Eye Disease is also expected to increase the growth of the target market. Growing healthcare setups and rising research and development activities in the region are factors increasing the growth of the target market in the region. In addition, the region Asia Pacific is projected to grow rapidly in the global Thyroid Eye Disease market due to growing concerns about thyroid eye disease, increasing healthcare expenditure, government initiatives, and increasing funding in various industries.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 2.26 Bn |
| Revenue Forecast In 2034 | USD 4.02 Bn |
| Growth Rate CAGR | CAGR of 6.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Marketed Products, Pipeline treatment |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Horizon Therapeutics, Viridian Therapeutics, Pierre Fabre/ACELYRIN, HanAll Biopharma/Harbour BioMed/Immunovant, and Sling Therapeutics. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.